Search

OBJ signs research agreement with GlaxoSmithKline Healthcare

Pharmaceutical giant GlaxoSmithKline Consumer Healthcare has signed a short term arrangement with Leederville-based transdermal drug delivery company OBJ Ltd to carry out studies into the use of its technology on a range of nonprescription applications.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

OBJ (OBJ)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/03/18

1 year TSR5 year TSR
145thLiveHire68%0%
153rdRBR67%-14%
748thOBJ-57%18%
716 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

02/02/18
$0 Other
02/02/18
$0 Other
31/08/17
$0 Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

131st↓OBJ$1.8m
139th-RBR$1.3m
140th↓LiveHire$1.3m
142nd↓AnaeCo$1.2m
143rd-MOKO Social Media$1.2m
236 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from OBJ

250thJeff Edwards$470k
667thChris Quirk$196k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer